Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 401–500 of 1,002
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease
Thomas, A. S., Hanauer, S. B., & Wang, Y. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.004 · Cited by 38
Cracking Brain Diseases from Gut Microbes-Mediated Metabolites for Precise Treatment
Gong, Y., Chen, A., Zhang, G., Shen, Q., Zou, L., Li, J., Miao, Y., & Liu, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85259 · Cited by 35
“Fecal microbiota transplantation can also overcome PD-1 resistance in patients with advanced melanoma [177].”
BackgroundZhuang, Y.-P., Zhou, H., Chen, H., Zheng, M.-Y., Liang, Y., Gu, Y.-T., Li, W., Qiu, W., & Zhou, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115040 · Cited by 37
Chen, Q., Zhu, Y., Wang, K., Wang, X., Zhang, Y., Zhou, M., Du, J., Qu, X., Shi, Z., Zhang, Y., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101994 · Cited by 38
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
Ríos-Hoyo, A., & Arriola, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221097 · Cited by 35
Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 36
“Another clinical study demon‑ strated that fecal transplantation from patients with melanoma who responded to anti‑PD‑1 therapy provided clinical benefit to 6 out of 15 patients with anti‑PD‑1 resistance (110).”
BackgroundAllegretti, J. R., Khanna, S., Mullish, B. H., & Feuerstadt, P. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.004 · Cited by 37
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Zhang, M., Bzura, A., Baitei, E. Y., Zhou, Z., Spicer, J., Poile, C., Rogel, J., Branson, A., King, A., Barber, S. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49842-5 · Cited by 38
Zhu, Z., Cheng, Y., Liu, X., Xu, X., Ding, W., Ling, Z., Liu, J., & Cai, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1644160 · Cited by 60
Zhao, H., Wang, D., Zhang, Z., Xian, J., & Bai, X. (2022) · Molecules · doi:10.3390/molecules27154799 · Cited by 38
“This strategy has been applied in several clinical trials and performed well [5].”
BackgroundMethodNinkov, M., Schmerk, C. L., Moradizadeh, M., Parvathy, S. N., Figueredo, R., Burton, J. P., Silverman, M. S., Fernandes, R., Maleki Vareki, S., & Haeryfar, S. M. M. (2023) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03329-8 · Cited by 32
“FMT has been employed in recent preclinical studies and clinical trials to improve the efficacy of programmed cell death-1 (PD-1)-based ICIs in cancer [8, 9, 23].”
MethodEntezari, M., Abad, G. G. Y., Sedghi, B., Ettehadi, R., Asadi, S., Beiranvand, R., Haratian, N., Karimian, S. S., Jebali, A., Khorrami, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115673 · Cited by 36
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 38
“In the KEYNOTE 164 study, nine dMMR mCRC patients who had progressive disease (PD) after pem- brolizumab received a second course of pembrolizumab; six of whom achieved PR.115 In the GERCOR NIPICOL study, three dMMR mCRC patients who had PD after nivolumab plus ipilimumab received a second course of nivolumab; two of…”
BackgroundCheckpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
Zeriouh, M., Raskov, H., Kvich, L., Gögenür, I., & Bennedsen, A. L. B. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100923 · Cited by 33
Exploiting the gut microbiome for brain tumour treatment
Keane, L., Cryan, J. F., & Gleeson, J. P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.08.008 · Cited by 33
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Human Microbiome and Its Medical Applications
Zhang, Y., Zhou, L., Xia, J., Dong, C., & Luo, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703585 · Cited by 32
“FMT increases the levels of Bifidobacterium longum and Faecalibacterium prausnitzii in the gut of patients with PD1 refractory melanoma, which were associated with effective immunotherapy responsiveness, and thus improves immunotherapy outcomes in some patients with a favorable safety profile (Davar et al., 2021).”
BackgroundRoles of Microbiota in Cancer: From Tumor Development to Treatment
Bagheri, Z., Moeinzadeh, L., & Razmkhah, M. (2022) · Journal of Oncology · doi:10.1155/2022/3845104 · Cited by 35
“Indeed, FMT administered via colonoscopy reprogrammed the microenvironment of tumor by changing the gut microbiota composition in patients with PD-1 refractory melanoma that consequently improved the anti-PD-1 responses [175].”
MethodInteraction between gut microbiota and immune checkpoint inhibitor-related colitis
Zhou, G., Zhang, N., Meng, K., & Pan, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001623 · Cited by 39
“Fecal microbiota transplantation (FMT) has also demonstrated the ability of overcoming resistance to anti-PD-1 therapy in melanoma patients (15).”
BackgroundQueen, J., Shaikh, F. Y., & Sears, C. L. (2023) · Nature Cancer · doi:10.1038/s43018-023-00602-2 · Cited by 36
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma
Shen, S., Khatiwada, S., Behary, J., Kim, R., & Zekry, A. (2022) · Cancers · doi:10.3390/cancers14092099 · Cited by 34
“that FMT with subsequent αPD-1 therapy is not only safe, but also shows promise in altering the gut microbiota, metabolite profiles, and, ultimately, skewing towards an antitumour immune response in initially ICI nonresponders [64,65].”
BackgroundMethodInfluentialThe bacterial microbiome and cancer: development, diagnosis, treatment, and future directions
Qasem, H., & El-Sayed, W. M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01523-9 · Cited by 34
“This shift in microbiota was associated with enhanced antitumor responses [83].”
InfluentialDeficient Mismatch Repair and Microsatellite Instability in Solid Tumors
Awosika, J. A., Gulley, J. L., & Pastor, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094394 · Cited by 42
“Results from completed studies support this concept [157,158].”
Takyi, E., Nirmalkar, K., Adams, J. B., & Krajmalnik‐Brown, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2499580 · Cited by 45
“167,168 Microbiota transfer therapy was used initially by Kang et al. 54 However, this term is being replaced with microbiota transplant therapy as this term transplant recognizes the need for human donors and the engraftment of donor microbiota into recipients.”
Intestinal dysbiosis and colorectal cancer
Kang, Z., Jiang, S., Fang, J., & Chen, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003617 · Cited by 38
“[151,152] A 2018 clinical study demonstrated that FMT alleviated refractory ICI-associated colitis, with marked improvement observed on endoscopic evaluation, including reduced inflammation and resolution of ulcerations.”
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
“The gut microbiota, consisting of trillions of microorganisms residing in the gastrointestinal tract, has emerged as a critical determinant of immune function and response to cancer immunotherapy, with several studies demonstrating association of microbiota composition with clinical response 10–16 .”
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
Bird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 31
Gut microbiota shed new light on the management of immune‐related adverse events
Tan, B., Liu, Y., Tang, H. T., Chen, D., Xu, Y., Chen, M., Li, Y., Wang, M., & Qian, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14626 · Cited by 36
“Recently, two clinical FMT studies demonstrated that allogeneic FMT from responders reversed primary anti-PD-1 resistance in 6/15 and 3/10 melanoma patients.(8,9) These results are promising, and modifications to the diverse baseline gut microbiota is likely to impact ICI efficacy through complex interactions between…”
BackgroundThe role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 34
Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30
“In fact, recent data from two pilot clinical trials suggest that fecal microbiota transfer (FMT) from patients with responsive tumors to anti-PD-1 nonresponsive patients with melanoma may enhance the anti-tumor response to ICIs in some cases [10, 11].”
BackgroundMicrobiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
“A successful FMT results in a persistent shift in the recipient’s gut microbiome toward the composition of the donor’s microbiota (Davar et al. 2021).”
BackgroundInfluence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“Nonetheless, future research undertakings should incorporate ICI biomarkers, including PD-L1 expression and tumor mutational burden, to assess the indispensable role of pre-existing adaptive immunity in facilitating effective FMT [270,271].”
BackgroundFaecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome
Ghani, R., Chrysostomou, D., Roberts, L. A., Pandiaraja, M., Marchesi, J. R., & Mullish, B. H. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2423026 · Cited by 33
“28,29 However, these studies had no comparator arm using ‘standard’ healthy donors, making it difficult to ascertain if the response seen was related to using a drug responder, or just a general effect.”
Rizzo, A. E., Gordon, J., Berard, A. R., Burgener, A., & Avril, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060546 · Cited by 33
Establishment and Resilience of Transplanted Gut Microbiota in Aged Mice
Wang, Y., Tang, J., Lv, Q., Tan, Y., Dong, X., Liu, H., Zhao, N., He, Z., Kou, Y., Tan, Y. Q., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103654 · Cited by 39
The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
Modica, M. D., Arlotta, V., Sfondrini, L., Tagliabue, E., & Triulzi, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947188 · Cited by 36
Liu, X., Tang, H. T., Zhou, Q., Zeng, Y., Lu, B., Chen, D., Li, Y., Qian, J., Chen, M., Zhao, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109281 · Cited by 35
“Two recent clinical studies showed that FMT from ICI responders to primary non-responders partially reversed ICI efficacy in melanoma patients (8, 9).”
BackgroundAlvarado-Peña, N., Galeana-Cadena, D., Gómez-García, I. A., Mainero, X. S., & Silva‐Herzog, E. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1237998 · Cited by 31
Farias, R. M., Jiang, Y., Levy, E. J., Hwang, C. H., Wang, J., Burton, E. M., Cohen, L. G., Ajami, N., Wargo, J. A., Daniel, C. R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13234-1 · Cited by 42
Ioannou, P., Katsoulieris, E. N., & Afratis, N. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083621 · Cited by 36
“…demonstrated that FMT combined with anti-PD-1 therapy was well tolerated and provided clinical benefits in a subset of PD-1-refractory melanoma patients by modulating the gut microbiome, enhancing CD8+ T cell activation, and altering the tumor microenvironment to overcome therapy resistance [370].”
A review of engraftment assessments following fecal microbiota transplant
Herman, C., Barker, B. M., Bartelli, T. F., Chandra, V., Krajmalnik‐Brown, R., Jewell, M., Li, L., Liao, C., McAllister, F. M., Nirmalkar, K., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2525478 · Cited by 36
“12,33,34,36,41,59,70,74 For example, Kang et al. 34 found that Unweighted Unifrac distance to the donated microbiome decreased after administration of the FMT and concluded high FMT engraftment.”
Sakurai, T., Velasco, M. A. D., Sakai, K., Nagai, T., Nishiyama, H., Hashimoto, K., Uemura, H., Kawakami, H., Nakagawa, K., Ogata, H., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13062 · Cited by 30
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
“Firstly, Davar et al (50) demonstrated that in patients with MM, the GM composition was associated with the anti‐PD‐1 response.”
BackgroundInfluentialmiRNA as a Modulator of Immunotherapy and Immune Response in Melanoma
Nguyen, M.-H. T., Luo, Y.-H., Li, A.-L., Tsai, J.-C., Wu, K., Chung, P., & Ma, N. J.-L. (2021) · Biomolecules · doi:10.3390/biom11111648 · Cited by 33
“A clinical trial (NCT03341143) was conducted to assess the effects of FMT in melanoma patients resistant to anti-PD-1 treatment whether alone or in combination with anti-CTLA-4 [44].”
BackgroundThompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 32
“Furthermore, two interventional studies in advanced melanoma have demonstrated that faecal microbiota transplant (FMT) can convert patients that have previously progressed on anti-PD1 immunotherapy to become responsive [22, 23].”
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Zheng, M., Zhou, W., Huang, C., Hu, Z. Q., Zhang, B., Lu, Q., & Zhao, M. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102989 · Cited by 29
Xin, Y., Liu, C., Zang, D., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343450 · Cited by 39
Zareie, P., Weiss, E. S., Kaplan, D. H., & Mackay, L. K. (2025) · Nature Immunology · doi:10.1038/s41590-025-02145-3 · Cited by 29
“Interestingly, this might not be limited to skin commensals, as fecal microbiota transplantation has shown clinical promise for melanoma treatment 143,144 .”
Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 33
“Both trials demonstrated signs of therapeutic bene fi t in some treated patients, including a higher abundance of taxa associated with an anti – PD-1 response and enhanced CD8 + T cell activation (82, 83).”
BackgroundMicrobiome in Cancer Development and Treatment
Čierniková, S., Ševčíková, A., Mladosievičová, B., & Mego, M. (2023) · Microorganisms · doi:10.3390/microorganisms12010024 · Cited by 32
“It also involves the expansion of cytotoxic CD8 cells associated with the upregulation of perforin and serine protease granzyme, leading to apoptotic destruction of tumor cells [138,139].”
BackgroundLiu, Y., Kim, E. S., & Guo, H. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29485 · Cited by 31
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 39
“In a clinical trial led by Dr. Davar (NCT03341143), investigators assessed whether resistance to anti-PD-1 therapy can be overcome by changing the gut microbiota in patients with advanced melanoma (117).”
BackgroundYi, M., Li, T., Niu, M., Wu, Y., Zhao, B., Shen, Z., Hu, S., Zhang, C. H., Zhang, X., Zhang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202408598 · Cited by 40
Roy, S., Bahmani, A. H. A., Davids, M., Herrema, H., & Nieuwdorp, M. (2025) · Microorganisms · doi:10.3390/microorganisms13061356 · Cited by 29
“FMT from donors with previously favorable disease outcomes into patients with poor prognosis resulted in a larger clinical benefit compared to healthy donors [122].”
New perspective on fecal microbiota transplantation in liver diseases
Suk, K. T., & Koh, H. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15729 · Cited by 29
The Roles of the Virome in Cancer
Broecker, F., & Moelling, K. (2021) · Microorganisms · doi:10.3390/microorganisms9122538 · Cited by 34
“It has been shown recently that FMT using donor stool from responders can boost the response to checkpoint inhibitor therapy of previous nonresponder melanoma patients [105,106].”
BackgroundMethodResultInfluentialHersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy
Shelkey, E., Oommen, D., Stirling, E. R., Soto‐Pantoja, D. R., Cook, K. L., Lu, Y., Votanopoulos, K. I., & Söker, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13930-7 · Cited by 31
Local Breast Microbiota: A “New” Player on the Block
Vitorino, M. M., Costa, D. A., Vicente, R. S., Caleça, T., & Santos, C. (2022) · Cancers · doi:10.3390/cancers14153811 · Cited by 30
“These results support the concept of overcoming resistance to immu otherapy by modulating gut micr biota [33,34].”
ResultWilliams, K. C., Gault, A., Anderson, A. E., Stewart, C. J., Lamb, C. A., Speight, R. A., Rajan, N., Plummer, R., & Pratt, A. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122430 · Cited by 28
“Moreover, case reports have demonstrated faecal microbiota transplant (FMT) can mitigate both anti-PD-1 tumour-resistance and treatment-refractory GI-irAEs (39, 40), and antibiotic therapy is correlated with high-grade GI-irAE incidence (41) – all consistent with a critical immune-mediating role for the microbiome in…”
BackgroundInfluentialMicrobiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Song, R., Liu, F., Yu, P., Zhang, Y., & Wang, L. (2023) · Biomarker Research · doi:10.1186/s40364-023-00498-1 · Cited by 29
“Furthermore, the detection of ctDNA at week 8 also correlated with shorter PFS (median, 11 vs. 2 months; HR 10.2; 95% CI 2.5–41; P = 0.001) and OS (HR 15, P = 0.004) [37]. cfDNA mutation‑based biomarkers Blood‑based TMB In addition to quantification of cfDNA level, mutation characteristics of the genome may also help…”
BackgroundInfluentialHwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 29
“Enriched taxa in responders belonged to the phyla Firmicutes and Actinobacteria, whereas the phylum Bacteroidetes decreased in responders.(19)”
BackgroundYue, B., Gao, Y., Hu, Y., Zhan, M., Wu, Y., & Lu, L. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1731 · Cited by 31
Immunotherapy in melanoma: advances, pitfalls, and future perspectives
Sorino, C., Iezzi, S., Ciuffreda, L., & Falcone, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1403021 · Cited by 37
The role of short-chain fatty acids in cancer prevention and cancer treatment
Kalyanaraman, B., Cheng, G., & Hardy, M. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110172 · Cited by 34
“Fecal transplant overcame resistance to immunotherapy and enhanced anti-PD-1 efficacy [43,72,73].”
Crouch, L. I., Rodrigues, C. S., Bakshani, C. R., Tavares-Gomes, L., Gaifem, J., & Pinho, S. S. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101891 · Cited by 31
Tang, Y., Cai, Q., Tian, Z., Chen, W., & Tang, H. (2025) · Research · doi:10.34133/research.0600 · Cited by 35
Lifelong partners: Gut microbiota-immune cell interactions from infancy to old age
Brown, J. A., Bashir, H., & Zeng, M. Y. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.01.006 · Cited by 35
Jing, N., Wang, L., Zhuang, H., Jiang, G., & Liu, Z. (2021) · Cancers · doi:10.3390/cancers13163987 · Cited by 30
“Recent years have witnessed ever growing efforts in modulating the gut microbiome for improving responses to ICIs [4–9], through a wide variety of innovative strategies such as dietary interventions [10], administration of bacterial consortia or “Designer Probiotics” [11], and fecal microbiota transplantation (FMT) [1…”
BackgroundUsing the microbiome in clinical practice
Turjeman, S., & Koren, O. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13971 · Cited by 26
“, 2019), and preliminary results from two pilot studies in humans revealed that FMT can increase responsiveness to anti-PD-1 immunotherapy (Baruch et al., 2021; Davar et al., 2021).”
ResultRedrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Microbial mechanisms to improve immune checkpoint blockade responsiveness
Griffin, M. E., & Hang, H. C. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100818 · Cited by 31
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Regulation of T cell repertoires by commensal microbiota
Kim, K. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1004339 · Cited by 36
“Additionally, transplantation of fecal microbiota from the responders or healthy individuals made the non-responders become responsive to ICI treatment (Baruch et al., 2021; Davar et al., 2021).”
BackgroundThe impact of the microbiome in cancer: Targeting metabolism of cancer cells and host
Huang, J., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029033 · Cited by 28
“A clinical study of an Israeli team reveals that gut microbiota from responders can improve the efficacy to anti-PD-1-based immunotherapy for non-responders (73).”
BackgroundResultUnderstanding and harnessing triple-negative breast cancer-related microbiota in oncology
Devoy, C., Bueso, Y. F., & Tangney, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020121 · Cited by 33
Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response
Chai, Y., Huang, Z., Shen, X., Lin, T., Zhang, Y., Xu, F., Mao, Q., & Liang, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11051240 · Cited by 29
Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 31
“These results have subsequently been translated into clinical trials in patients with melanoma [29,30].”
BackgroundResultWang, Q., Jiang, B., Wei, M., He, Y., Wang, Y., Zhang, Q., Wei, H., & Tao, X. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127624 · Cited by 29
Lou, J., Cui, S., Li, J., Jin, G., Fan, Y., & Huang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1279680 · Cited by 32
“It has been widely proven that this method can overcome resistance to checkpoint inhibitor therapy in malignant melanoma, and reintroduce a clinical reaction post-FMT (67, 68).”
MethodJing, L., Lv, L., Zhong, L., Xu, F., Su, W., Chen, Y., Wu, Z., He, S., & Chen, Y. (2024) · Advanced Science · doi:10.1002/advs.202413128 · Cited by 28
Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., Palma, E. D., Cerbone, L., Grosso, F., Vecchia, M. L., Bona, E., et al. (2025) · Nutrients · doi:10.3390/nu17172898 · Cited by 30
“↓ bacteria diversity and ecological network function; ↓ butyric-producing bacteria [192,196] ↑ treatment response via CD8 + T cell and innate effectors activation; ↓ suppressive myeloid cells [204] Legend.”
Influence of the microbiome on solid organ transplant survival
Pirozzolo, I., Li, Z., Sepulveda, M., & Alegre, M. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.004 · Cited by 27
The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy
Kim, J.-H., & Lee, H. K. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0032 · Cited by 29
“In recent studies, FMT can overcomes the resistance to immunotherapy in melanoma patients whose cancers do not respond (Baruch et al., 2021; Davar et al., 2021).”
BackgroundCancer and immunotherapy: a role for microbiota composition
Pham, F., Moinard‐Butot, F., Coutzac, C., & Chaput, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.051 · Cited by 29
Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy
Bae, J., Park, K., & Kim, Y. (2022) · Immune Network · doi:10.4110/in.2022.22.e3 · Cited by 32
“In addition, FMT altered serum metabolites and cytokines in responders (87).”
BackgroundResultInfluentialThe Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
Oster, P., Vaillant, L., McMillan, B., & Velin, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899161 · Cited by 32
“Finally, it was recently described that fecal microbiota transplants overcome the resistance to anti–PD1 therapy in 30% of melanoma patients (16, 17).”
BackgroundThe “Light Knife” for Gastric Cancer: Photodynamic Therapy
Wang, H., Ewetse, M. P., Ma, C., Pu, W., Xu, B., He, P., Wang, Y., Zhu, J., & Chen, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010101 · Cited by 28
Self-citationBorgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10457-y · Cited by 33
“Recent published data of two phase I trials show that FMT and reintroduction of anti-PD-1 treatment in refractory metastatic melanoma patients is safe, feasible, and can be effective [27, 28].”
BackgroundMethodResultInfluentialGut Microbiome in Patients With Early-Stage and Late-Stage Melanoma
Witt, R. G., Cass, S. H., Tran, T., Damania, A. V., Nelson, E. E., Sirmans, E., Burton, E. M., Chelvanambi, M., Johnson, S. B., Tawbi, H. A., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2955 · Cited by 28
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 31
Wu, M., Tian, C., Zou, Z., Min, J., & Liu, H. (2024) · Cancers · doi:10.3390/cancers16203547 · Cited by 29
“Additionally, FMT can reprogram the tumor microenvironment to overcome resistance to PD-1 antibody treatment [164].”
BackgroundSaid, S., & Ibrahim, W. (2025) · Cancer Management and Research · doi:10.2147/cmar.s405590 · Cited by 25
“124”
Paternostro, R., Sieghart, W., Trauner, M., & Pinter, M. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100185 · Cited by 31
“fecal microbiota transplant) may help to overcome immunotherapy resistance and render tumors more susceptible to immune checkpoint blockers (ICBs).(85,86) Obesitydtypically associated with NAFLDdcan hamper antitumor immunity (Figure 2).”
BackgroundGut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
Zhou, Y., Liu, Z., & Chen, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847350 · Cited by 32
“claimed that patients carrying PD1-resistant melanoma could benefit from a combinatory approach of FMT and anti-PD1 therapy primarily through modulating microbiota composition and reprogramming the immune tone (81).”
BackgroundTomasi, M., Caproni, E., Benedet, M., Zanella, I., Giorgetta, S., Dalsass, M., König, E., Gagliardi, A., Fantappiè, L., Berti, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912639 · Cited by 25
“The observations that patients responding and non-responding to checkpoint inhibitors can be stratified based on their microbiome composition (40) and that the resistance to anti– PD-1 therapy in melanoma patients could be overcome by responder-derived fecal microbiota transplantation (FMT) (5) have prompted several l…”
Background
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.